Navigation Links
Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
Date:6/13/2012

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1). PD-1 is a key immune "checkpoint" receptor expressed by activated immune cells (T-cells) and is involved in the suppression of immunity.

The clinical trial, designed to assess the anti-tumor activity and safety of the treatment, was conducted with the help of 296 patients with a variety of cancers, including non-small cell lung cancer, melanoma and renal cell cancer, among others. Study results were published in a recent article in The New England Journal of Medicine.

According to study co-author Scott J. Antonia, M.D., Ph.D., chair of the Thoracic Oncology Program and co-chair of the Immunology Program at Moffitt, tumors can develop multiple resistance mechanisms to evade natural destruction by the body's immune system. Tumors may do this by exploiting a variety of biochemical pathways that lead to "immune checkpoints" where immune responses that might get through the checkpoints and otherwise help destroy tumor cells are, instead, terminated.

"There have been recent intensive efforts to develop immunotherapeutic approaches to treat cancer, including efforts to develop immune-checkpoint-pathway inhibitors," Antonia said. "A particular challenge in cancer immunotherapy has been to find the mechanism-based biomarkers that could be used to identify patients whose tumors are candidates for immune treatment."

For evidence that this approach is working, the study authors pointed to the recent success of the drug ipilimumab, an immune checkpoint pathway inhibitor that has been effective for many patients with advanced melanoma.

Their study results, Antonia said, suggested that tumors expressing the PD-1 ligand - PD-L1 (a ligand is binding molecule) - is an important candidate molecular marker. For example, in patients with PD-L1-positive tumors, the response to BMS-936558 was 36 percent, as opposed to no response in patients with PD-L1-negative tumors.

Among the 296 patient volunteers in whom responses could be evaluated, complete or partial responses resulted for those with non-small cell lung cancer, melanoma or renal cell cancer. The researchers concluded that the anti-PD-1 antibody was safe, effective and the responses were "durable."


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Boston researcher, surgical oncologist receives national award
11. Psychological testing may predict success in soccer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader in ... position of Executive Vice President, Sales and Marketing. Finnegan is a widely known ... device sales leadership. He has received industry recognition for innovations and new approaches ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands ... whether they can trust the sponsor to pay them correctly and on time. As ... CROs establish payment strategies that encourage sites to work on their studies. , At ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... Beverly Hills, California (PRWEB) , ... June 27, 2017 , ... ... implants market has been projected to reach a staggering $6.81 billion by the year ... implants are rising at a faster rate than those made from titanium. Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
Breaking Medicine Technology: